Bioretec Oy

Bioretec is a Finnish medical device company specializing in the design, development, and manufacturing of bioabsorbable orthopedic implants. Founded in 2003 and headquartered in Tampere, Finland, the company's mission is to leverage biology and technology to facilitate the body's natural healing processes, enabling patients to regain strength and mobility.

The company's product portfolio comprises two main lines: Activa™ and RemeOs™. Activa™ products are based on self-reinforced PLGA biopolymer and are utilized for treating small bone fractures, soft tissue lesions, and in pediatric surgery. The RemeOs™ product line, a newer generation, uses a high-performance magnesium alloy and hybrid composite, offering strong, absorbable implants designed to promote bone growth and eliminate the need for removal surgery. Bioretec's products are sold globally in approximately 40 countries, targeting the orthopedic trauma products market.

Bioretec is publicly traded on the Nasdaq First North Growth Market Finland under the ticker BRETEC. Recent developments include the RemeOs™ Trauma Screw receiving U.S. market authorization in March 2023 and CE mark approval in Europe in January 2025. Additionally, the RemeOs™ DrillPin was granted FDA Breakthrough Device Designation in December 2025. The company, led by CEO Sarah van Hellenberg Hubar-Fisher, is focused on expanding its RemeOs™ product series and establishing it as a leading absorbable metal alloy solution in the global orthopedic market.

Latest updates

Bioretec Stock Option Prices Plummet After Rights Issue

Event summary

  • Bioretec completed a rights issue on April 28, 2026, raising capital through the subscription of 1,286,801,534 new shares.
  • The new shares were registered with the Finnish Patent and Registration Office on April 28, 2026.
  • Bioretec has adjusted the subscription prices for its 2018-1A, 2018-1B, 2018-1C, 2018-1D, 2020-1A, 2020-1B, 2020-1C, 2023-1, and 2025-1 stock option programs.
  • Subscription prices have been significantly reduced, ranging from a prior price of EUR 1.42 to EUR 3.55, down to new prices between EUR 0.13 and EUR 0.33.

The big picture

The adjustment to stock option prices is a direct consequence of the recently completed rights issue, a move likely undertaken to secure funding for Bioretec’s continued expansion and product development. This action highlights the challenges faced by growth-stage medical device companies in balancing capital needs with shareholder and employee incentives. The significant price reductions signal a substantial dilution event for existing shareholders and option holders.

What we're watching

Employee Morale
The substantial reduction in stock option values may negatively impact employee morale and retention, particularly among those who joined the company with expectations of significant upside from these options.
Future Capital Needs
The rights issue and subsequent option price adjustments suggest Bioretec may require further capital infusions to fund its growth and expansion plans, potentially impacting future shareholder dilution.
Option Exercise Behavior
The drastically reduced subscription prices will likely influence the exercise behavior of option holders, potentially leading to a surge in share issuance if many choose to exercise their options.
CID: 2618